Market Cap : 3.75 B | Enterprise Value : 4.16 B | PE Ratio : At Loss | PB Ratio : 7.03 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Guardant Health's dividend payout ratio for the months ended in Mar. 2022 was 0.00.
The historical rank and industry rank for Guardant Health's Dividend Payout Ratio or its related term are showing as below:
As of today (2022-05-21), the Dividend Yield % of Guardant Health is 0.00%.
Guardant Health's Dividends per Share for the months ended in Mar. 2022 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Guardant Health's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Guardant Health's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Guardant Health's Dividend Payout Ratio falls into.
Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.
Guardant Health's Dividend Payout Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Dividend Payout Ratio | = | Dividends per Share (A: Dec. 2021 ) | / | EPS without NRI (A: Dec. 2021 ) |
= | 0 | / | -4 | |
= | N/A |
Guardant Health's Dividend Payout Ratio for the quarter that ended in Mar. 2022 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Mar. 2022 ) | / | EPS without NRI (Q: Mar. 2022 ) |
= | 0 | / | -1.21 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Guardant Health's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By Fool 2022-01-12
By Zacks 2022-01-27
By Zacks 2021-11-03
By Fool 2022-03-08
By tipranks.com 2022-03-10
By Seekingalpha 2022-01-03
By tipranks.com 2022-04-05
By Zacks 2022-01-26
By tipranks.com 2022-03-05
By Zacks 2021-08-05
By Seekingalpha 2021-11-04
By Zacks 2022-02-11
By Fool 2021-10-01